Carcinomatous meningitis: antibody-guided therapy with I-131 HMFG1.
Seven patients with carcinomatous meningitis were administered intrathecal I-131 labelled monoclonal antibody HMFG1. Clinical responses were seen in two patients, with a long term survivor at 32 months. Aseptic meningitis occurred in 4/7 patients, but more serious toxicity was observed in the form of seizures (2/7 patients) and myelosuppression (3/7 patients). Partial obliteration of the subarachnoid space was identified as a potential problem in patients with advanced disease.
Moseley
R P
RP
Frenchay Hospital, Bristol, UK.
Benjamin
J C
JC
Ashpole
R D
RD
Sullivan
N M
NM
Bullimore
J A
JA
Coakham
H B
HB
Kemshead
J T
JT
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000918:Antibody Specificity / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008562:Membrane Glycoproteins / Q000276:immunology*; D008577:Meningeal Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary*; D008581:Meningitis / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D008875:Middle Aged; D018396:Mucin-1; D009460:Neurologic Examination; D011877:Radionuclide Imaging
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D007457:Iodine Radioisotopes; D008562:Membrane Glycoproteins; D018396:Mucin-1